RPAM
IGMS

Rhenman & Partners Asset Management’s IGM Biosciences IGMS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-126,064
Closed -$770K – 97
2024
Q4 		$770K Sell
126,064
-59,395
-32% -$706K 0.08% 90
2024
Q3 		$3.07M Sell
185,459
-9,541
-5% -$105K 0.25% 82
2024
Q2 		$1.34M Hold
195,000
– – 0.13% 84
2024
Q1 		$1.88M Sell
195,000
-5,000
-3% -$57.9K 0.18% 77
2023
Q4 		$1.66M Hold
200,000
– – 0.17% 76
2023
Q3 		$1.67M Hold
200,000
– – 0.18% 74
2023
Q2 		$1.85M Buy
200,000
+105,000
+111% +$1.18M 0.19% 76
2023
Q1 		$1.62M Buy
95,000
+45,000
+90% +$931K 0.18% 78
2022
Q4 		$851K Buy
+50,000
New +$1M 0.09% 92

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Rhenman & Partners Asset Management's IGMS Position: Q1 2025 in Review

Rhenman & Partners Asset Management sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 126,064 shares — an estimated $770K sold.

Rhenman & Partners Asset Management first reported a position in IGMS in Q4 2022 and held it in 9 quarters. The position peaked at $3.07M in Q3 2024. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • Rhenman & Partners Asset Management reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 126,064 IGM Biosciences shares in Q1 2025, an estimated $770K.
  • Rhenman & Partners Asset Management first reported a position in IGM Biosciences in Q4 2022 and held it in 9 quarters.
  • Rhenman & Partners Asset Management's IGM Biosciences position peaked at $3.07M in Q3 2024.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.